684 related articles for article (PubMed ID: 21572428)
1. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.
Pan X; Zhou T; Tai YH; Wang C; Zhao J; Cao Y; Chen Y; Zhang PJ; Yu M; Zhen C; Mu R; Bai ZF; Li HY; Li AL; Liang B; Jian Z; Zhang WN; Man JH; Gao YF; Gong WL; Wei LX; Zhang XM
Nat Med; 2011 Jun; 17(6):708-14. PubMed ID: 21572428
[TBL] [Abstract][Full Text] [Related]
2. A CUE hints at tumor resistance.
Thomas C; Gustafsson JA
Nat Med; 2011 Jun; 17(6):658-60. PubMed ID: 21647141
[No Abstract] [Full Text] [Related]
3. CUEDC2: an emerging key player in inflammation and tumorigenesis.
Man J; Zhang X
Protein Cell; 2011 Sep; 2(9):699-703. PubMed ID: 21976060
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
[TBL] [Abstract][Full Text] [Related]
5. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome.
Zhang PJ; Zhao J; Li HY; Man JH; He K; Zhou T; Pan X; Li AL; Gong WL; Jin BF; Xia Q; Yu M; Shen BF; Zhang XM
EMBO J; 2007 Apr; 26(7):1831-42. PubMed ID: 17347654
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
7. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
8. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
9. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
10. Molecular crosstalk between CUEDC2 and ERα influences the clinical outcome by regulating mitosis in breast cancer.
Roy S; Saha S; Dhar D; Chakraborty P; Singha Roy K; Mukherjee C; Gupta A; Bhattacharyya S; Roy A; Sengupta S; Roychoudhury S; Nath S
Cancer Gene Ther; 2022 Nov; 29(11):1697-1706. PubMed ID: 35732909
[TBL] [Abstract][Full Text] [Related]
11. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
12. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
13. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
14. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
15. USP9X downregulation renders breast cancer cells resistant to tamoxifen.
Oosterkamp HM; Hijmans EM; Brummelkamp TR; Canisius S; Wessels LF; Zwart W; Bernards R
Cancer Res; 2014 Jul; 74(14):3810-20. PubMed ID: 25028367
[TBL] [Abstract][Full Text] [Related]
16. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
17. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
18. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
Schiff R; Osborne CK
Breast Cancer Res; 2005; 7(5):205-11. PubMed ID: 16168139
[TBL] [Abstract][Full Text] [Related]
19. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
20. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
